Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
McKesson
Moodys

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

EVOTAZ Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Evotaz, and what generic alternatives are available?

Evotaz is a drug marketed by Bristol-myers Squibb and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and thirteen patent family members in fifty-two countries.

The generic ingredient in EVOTAZ is atazanavir sulfate; cobicistat. There are twenty-five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the atazanavir sulfate; cobicistat profile page.

Drug patent expirations by year for EVOTAZ
Drug Prices for EVOTAZ

See drug prices for EVOTAZ

Generic Entry Opportunity Date for EVOTAZ
Generic Entry Date for EVOTAZ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EVOTAZ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Gilead SciencesPhase 3
Bristol-Myers SquibbPhase 1
St Stephens Aids TrustPhase 1

See all EVOTAZ clinical trials

Recent Litigation for EVOTAZ

Identify potential future generic entrants

District Court Litigation
Case NameDate
Bristol-Myers Squibb Company v. Apotex Inc.2017-10-24
Gilead Sciences, Inc. v. Mylan Pharmaceuticals Inc.2017-02-22
Gilead Sciences Inc. v. Mylan Pharmaceuticals Inc.2016-03-25

See all EVOTAZ litigation

Synonyms for EVOTAZ
Atazanavir / cobicistat
Atazanavir and cobicistat
Atazanavir mixture with cobicistat
Cobicistat / Atazanavir
S900006860
Paragraph IV (Patent) Challenges for EVOTAZ
Tradename Dosage Ingredient NDA Submissiondate
EVOTAZ TABLET;ORAL atazanavir sulfate; cobicistat 206353 2017-09-13

US Patents and Regulatory Information for EVOTAZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol-myers Squibb EVOTAZ atazanavir sulfate; cobicistat TABLET;ORAL 206353-001 Jan 29, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Bristol-myers Squibb EVOTAZ atazanavir sulfate; cobicistat TABLET;ORAL 206353-001 Jan 29, 2015 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Bristol-myers Squibb EVOTAZ atazanavir sulfate; cobicistat TABLET;ORAL 206353-001 Jan 29, 2015 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EVOTAZ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol-myers Squibb EVOTAZ atazanavir sulfate; cobicistat TABLET;ORAL 206353-001 Jan 29, 2015   Start Trial   Start Trial
Bristol-myers Squibb EVOTAZ atazanavir sulfate; cobicistat TABLET;ORAL 206353-001 Jan 29, 2015   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for EVOTAZ

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2487162 122016000103 Germany   Start Trial PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ ODER SOLVAT DAVON UND DARUNAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ ODER SOLVAT DAVON, INSBESONDERE DARUNAVIRETHANOLAT; REGISTRATION NO/DATE: EU/1/14/967 20141119
2487163 60/2016 Austria   Start Trial PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE ATAZANAVIR-SULFAT; REGISTRATION NO/DATE: EU/1/15/1025 (MITTEILUNG) 20150715
2049506 262 5024-2015 Slovakia   Start Trial PRODUCT NAME: KOBICISTAT VO VSETKYCH FORMACH CHRANENYCH ZA-; REGISTRATION NO/DATE: EU/1/13/830 20130527
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKinsey
Dow
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.